Rene Rodriguez
Overview
Explore the profile of Rene Rodriguez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rey V, Tornin J, Alba-Linares J, Robledo C, Murillo D, Rodriguez A, et al.
EBioMedicine
. 2024 Mar;
102:105090.
PMID: 38547578
Background: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to...
2.
Tornin J, Gallego B, Rey V, Murillo D, Huergo C, Rodriguez A, et al.
Free Radic Biol Med
. 2023 Oct;
209(Pt 1):127-134.
PMID: 37844652
Osteosarcoma (OS) is an aggressive bone cancer with poor prognosis, largely due to the limited effectiveness of current treatments such as doxorubicin (DX). Developing ways to overcome DX resistance is...
3.
Mensali N, Koksal H, Joaquina S, Wernhoff P, Casey N, Romecin P, et al.
Nat Commun
. 2023 Jun;
14(1):3375.
PMID: 37291203
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other...
4.
Estupinan O, Rey V, Tornin J, Murillo D, Gallego B, Huergo C, et al.
Biomed Pharmacother
. 2023 Apr;
162:114627.
PMID: 37018985
Osteosarcomas are frequently associated to a poor prognosis and a modest response to current treatments. EC-8042 is a well-tolerated mithramycin analog that has demonstrated an efficient ability to eliminate tumor...
5.
Tornin J, Mateu-Sanz M, Rey V, Murillo D, Huergo C, Gallego B, et al.
Redox Biol
. 2023 Mar;
62:102685.
PMID: 36989573
Osteosarcoma (OS) is a malignant type of bone cancer that arises in periods of increased bone formation. Curative strategies for these types of tumors have remained essentially unchanged for decades...
6.
Granda-Diaz R, Manterola L, Hermida-Prado F, Rodriguez R, Santos L, Garcia-de-la-Fuente V, et al.
Biomed Pharmacother
. 2023 Mar;
161:114512.
PMID: 36931033
Treatment of head and neck squamous cell carcinomas (HNSCC), the sixth most frequent cancer worldwide, remains challenging. miRNA dysregulation is closely linked to tumorigenesis and tumor progression, thus emerging as...
7.
Murillo D, Huergo C, Gallego B, Rodriguez R, Tornin J
Biomedicines
. 2023 Jan;
11(1).
PMID: 36672716
Drug resistance is a major problem in cancer treatment, as it limits the effectiveness of pharmacological agents and can lead to disease progression. Cold atmospheric plasma (CAP) is a technology...
8.
Keshavamurthy S, Duncan A, Kumar A, Trombetta C, Rodriguez R, Tan C, et al.
Cureus
. 2022 Oct;
14(9):e28961.
PMID: 36237781
Hunter syndrome is a rare disorder in which affected patients have significant airway abnormalities (macroglossia, small mouth opening, and supraglottic narrowing) that complicate their management. Deposition of glycosaminoglycans in the...
9.
Gallego B, Murillo D, Rey V, Huergo C, Estupinan O, Rodriguez A, et al.
Int J Mol Sci
. 2022 Jun;
23(12).
PMID: 35742867
Bone sarcomas have not shown a significant improvement in survival for decades, due, in part, to the development of resistance to current systemic treatments, such as doxorubicin. To better understand...
10.
Ortal A, Rodriguez A, Solis-Hernandez M, de Prado M, Rey V, Tornin J, et al.
Sci Rep
. 2022 Apr;
12(1):6911.
PMID: 35484295
Sarcomas are mesenchymal cancers which often show an aggressive behavior and patient survival largely depends on an early detection. In last years, much attention has been given to the fact...